(Sharecast News) - Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing significant improvements in progression-free survival for patients with late-stage melanoma.
The AIM-traded firm said the data, presented in an oral session at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE